GGrantIndex
← Leaderboards

Frank Pajonk

University Of California Los Angeles

$12,966,735
Attributed
$12,966,735
Total exposure
9
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY200925
$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,966,735 · 9

By mechanism

R01$8,598,233 · 5
U19$2,220,116 · 1
P50$2,148,386 · 3

Top collaborators

No co-investigators on record.

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsRadiationIn VivoStem CellsTumorRadiation TherapyIn VitroMalignant NeoplasmsTreatment FailureAffectPreventPhenotypeGlioblastomaGliomaCancer Stem CellGenerationsRadioresistantClinical TrialsCombined Modality TherapyEffective TherapyPublishingSelf-RenewalPathway InteractionsRecurrence

Grant awards (38)

Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy$509,555
R01 · FY2025 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$462,651
R01 · FY2025 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$54,237
R01 · FY2025 · CA · contact PI
Project 3: Strategies against radiation-induced cellular plasticity in glioblastoma$8,612
P50 · FY2025 · CA · contact PI
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy$484,078
R01 · FY2024 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$439,519
R01 · FY2024 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$102,267
R01 · FY2024 · CA · contact PI
Utilizing Radiation-Induced Multi-potency to Increase the Efficacy of Radiotherapy$507,937
R01 · FY2023 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$453,398
R01 · FY2023 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$105,497
R01 · FY2023 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$462,651
R01 · FY2022 · CA · contact PI
Project 3: Strategies against radiation-induced cellular plasticity in glioblastoma$370,368
P50 · FY2022 · CA · contact PI
Use of CTEP portfolio compounds to counteract phenotype conversion in GBM$54,237
R01 · FY2022 · CA · contact PI
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma$345,841
P50 · FY2021 · CA · contact PI
Glioblastoma, Glioblastoma Stem Cells and Radiotherapy$370,789
R01 · FY2020 · CA · contact PI
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma$353,405
P50 · FY2020 · CA · contact PI
Radiation Mitigation and Normal Tissue Stem Cells$430,742
U19 · FY2019 · AI · contact PI
Glioblastoma, Glioblastoma Stem Cells and Radiotherapy$359,664
R01 · FY2019 · CA · contact PI
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma$345,840
P50 · FY2019 · CA · contact PI
Radiation Mitigation and Normal Tissue Stem Cells$453,626
U19 · FY2018 · AI · contact PI
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma$372,138
P50 · FY2018 · CA · contact PI
Glioblastoma, Glioblastoma Stem Cells and Radiotherapy$370,789
R01 · FY2018 · CA · contact PI
Radiation Mitigation and Normal Tissue Stem Cells$427,632
U19 · FY2017 · AI · contact PI
Glioblastoma, Glioblastoma Stem Cells and Radiotherapy$370,789
R01 · FY2017 · CA · contact PI
Project 3: Inhibition of radiation-induced phenotype conversion in glioblastoma$352,182
P50 · FY2017 · CA · contact PI
Radiation Mitigation and Normal Tissue Stem Cells$446,395
U19 · FY2016 · AI · contact PI
Glioblastoma, Glioblastoma Stem Cells and Radiotherapy$370,789
R01 · FY2016 · CA · contact PI
Erythropoietin and Breast Cancer Stem Cells$319,550
R01 · FY2016 · CA · contact PI
Radiation Mitigation and Normal Tissue Stem Cells$461,721
U19 · FY2015 · AI · contact PI
Erythropoietin and Breast Cancer Stem Cells$319,550
R01 · FY2015 · CA · contact PI
Erythropoietin and Breast Cancer Stem Cells$309,964
R01 · FY2014 · CA · contact PI
Erythropoietin and Breast Cancer Stem Cells$300,377
R01 · FY2013 · CA · contact PI
The 26S Proteasome in Cancer Stem Cells$291,367
R01 · FY2013 · CA · contact PI
Erythropoietin and Breast Cancer Stem Cells$319,550
R01 · FY2012 · CA · contact PI
The 26S Proteasome in Cancer Stem Cells$309,964
R01 · FY2012 · CA · contact PI
The 26S Proteasome in Cancer Stem Cells$309,964
R01 · FY2011 · CA · contact PI
The 26S Proteasome in Cancer Stem Cells$319,550
R01 · FY2010 · CA · contact PI
The 26S Proteasome in Cancer Stem Cells$319,550
R01 · FY2009 · CA · contact PI